Fluzoparib Clinical Trials
11 recruitingDrug
Phase 29Phase 32
Showing 1–11 of 11 trials
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 3
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200 enrolled1 locationNCT06255392
Recruiting
Phase 2
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Sarcoma,Soft TissueBrachytherapyPoly(ADP-ribose) Polymerase Inhibitors
Fujun Zhang32 enrolled1 locationNCT05894018
Recruiting
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Qilu Hospital of Shandong University105 enrolled1 locationNCT06735326
Recruiting
Phase 2
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Ovarian Cancer
Qilu Hospital of Shandong University48 enrolled1 locationNCT06541314
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 2
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Huazhong University of Science and Technology33 enrolled1 locationNCT06516445
Recruiting
Phase 2
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992
Recruiting
Phase 3
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Breast Cancer
Fudan University766 enrolled15 locationsNCT05891093
Recruiting
Phase 2
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Breast Cancer Metastatic
Fudan University200 enrolled1 locationNCT05759546
Recruiting
Phase 2
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Her-2 Negative Breast CancerHRR Gene Mutation
Ying Lin66 enrolled1 locationNCT05761470